First-line chemoimmunotherapy and immunotherapy in patients with non-small cell lung cancer and brain metastases: a registry study
Lauren Brown(Garvan Institute of Medical Research), Benjamin Y. Kong(The University of Sydney), Victor Khou(The University of Sydney), Marliese Alexander(The University of Melbourne), Antony Mersiades(The University of Sydney), Wei Yen Chan(The University of Sydney), Joe Wei(Royal North Shore Hospital), Dasantha Jayamanne(The University of Sydney), Inês Pires da Silva(The University of Sydney), Adnan Nagrial(The University of Sydney), Chris Brown(The University of Sydney), Eric Hau(The University of Sydney), Stephen Clarke(The University of Sydney), Michael Boyer(Heidelberg University), Nick Pavlakis(The University of Sydney), Lydia Warburton(Edith Cowan University), Jenny Lee(Blacktown & Mount Druitt Hospital), Lauren Gray(Royal North Shore Hospital), Samuel Smith(Chris O’Brien Lifehouse), Malinda Itchins(The University of Sydney), Steven Kao(Chris O’Brien Lifehouse), Susan Harden(Johns Hopkins University)
Cited by 6
Related Papers
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
|Journal of Clinical Oncology|2003|3.1k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
|The Lancet Oncology|2016|1.2k
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
|JAMA Oncology|2015|656